SRPT logo

Sarepta Therapeutics, Inc.

SRPT
Healthcare|Biotechnology|US
$17.82
+0.25 (+1.42%)
Tangible Book / Share
$14.15
Graham Number
$6.73
Cash / Share
$8.30

About

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.

Stock Price

+1.0%(1Y)
1M
-2.1%
3M
+6.2%
6M
-10.7%
YTD
-17.2%
1Y
+3.2%
3Y
-77.9%
5Y
-80.0%

Pipeline Summary

59 total trials
31
Phase 1
22
Phase 2
9
Phase 3
2
Phase 4
Terminated: 15Completed: 26By Invitation: 5Unknown: 1Active: 7Recruiting: 3Withdrawn: 2

Active Trials (10)

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
NCT05881408Duchenne Muscular Dystrophy
Phase 3Active
Enrollment: 148 participants
Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
NCT07542314Duchenne Muscular Dystrophy
Phase 4Recruiting
Enrollment: 20 participants
A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
NCT05876780Limb Girdle Muscular Dystrophy
Phase 1Active
Enrollment: 6 participants
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
NCT03992430Muscular Dystrophy, Duchenne
Phase 3Active
Enrollment: 160 participants
Early Check: Expanded Screening in Newborns
NCT03655223Spinal Muscular Atrophy
Active
Enrollment: 30,000 participants

BioScore

6.3/10
Watchlist

Key Facts

Market Cap$1.88B
Employees835 (-39% YoY)
CEOMichael E. Severino
IPO DateJun 4, 1997
Beta0.20
52-Week Range$14.68 – $24.68
Avg Volume2,892,093
ExchangeNASDAQ

Ownership

Float95.1%
Shares Outstanding105.6M

Recent Insider Trades

Wong Ryan Ho-YanTAX W/H
Sep 4, 202613,272 shares @ $22.22
Estepan Ian MichaelTAX W/H
Sep 4, 202624,799 shares @ $22.22
Rothfuss CristinTAX W/H
Sep 4, 202622,025 shares @ $22.22
Rodino-Klapac LouiseTAX W/H
Sep 4, 202621,423 shares @ $22.22
SEVERINO MICHAELAWARD
Jul 28, 20262,224,342 shares @ $17.74

Peers

ALNYAlnylam Pharmaceuticals, Inc.
$20.89B
CAPRCapricor Therapeutics, Inc.
$521.2M
DSGNDesign Therapeutics, Inc.
$639.0M
DYNDyne Therapeutics, Inc.
$3.37B
IONSIonis Pharmaceuticals, Inc.
$6.55B
NTLAIntellia Therapeutics, Inc.
$1.59B
PEPGPepGen Inc.
$170.8M
PTCTPTC Therapeutics, Inc.
$5.47B
Data last updated: Nov 9, 2026, 04:35 AM